News about "Pfizer"

Pfizer and Valneva's Lyme Disease Vaccine Candidate Moves to EMA Review

Pfizer and Valneva’s investigational Lyme disease vaccine PF-07307405 has received EMA validation for its Marketing Authorization Application, triggering the European regulatory review.

Pfizer | 17/08/2026 | By News Bureau

Sun Pharma Wins Key US Appeals Court Ruling in Lipitor Antitrust Litigation

Sun Pharma wins a key US appeals court ruling in the Lipitor antitrust case, with summary judgment upheld in favor of the company and its subsidiaries.

Pfizer | 17/08/2026 | By News Bureau |  122

Pfizer and Valneva's Lyme Vaccine Candidate Gets EMA Review Validation

Pfizer and Valneva’s Lyme disease vaccine candidate receives validation from the European Medicines Agency (EMA), supported by more than 70 percent efficacy in the phase 3 VALOR trial.

Pfizer | 14/08/2026 | By News Bureau

Pfizer Reports Positive Phase 3 Results for LITFULO in Vitiligo

Pfizer's phase 3 studies showed LITFULO significantly improved facial and total repigmentation in patients with nonsegmental vitiligo versus placebo.

Pfizer | 31/07/2026 | By News Bureau

EU Approves Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine

The European Commission (EC) has approved Pfizer-BioNTech's XFG-adapted COVID-19 vaccine, with more than 5 billion vaccine doses distributed worldwide.

Pfizer | 30/07/2026 | By News Bureau

Bluesight and Pfizer Partner to Expand RFID-Tagged Medications for Hospitals

Bluesight and Pfizer are bringing source-tagged Radio Frequency Identification (RFID) SmartDose medications to hospital pharmacies, streamlining inventory management and reducing manual tagging.

Pfizer | 24/07/2026 | By News Bureau

US FDA Approves Pfizer's Ibrance for Maintenance Treatment of HR+, HER2+ Metastatic Breast Cancer

FDA approval makes Ibrance the first CDK4/6 inhibitor indicated for HR+ metastatic breast cancer regardless of HER2 status.

Pfizer | 26/06/2026 | By News Bureau |  259

US FDA Approves Pfizer's HYMPAVZI for Treatment of Additional Hemophilia A and B Patients

Pfizer’s HYMPAVZI has received expanded US FDA approval for hemophilia A and B patients aged 12 years and older with inhibitors, as well as children aged 6-11 years with or without inhibitors. The approval makes HYMPAVZI the first subcutaneous non-factor therapy available for pediatric hemophilia B patients ages 6 to 11 years old.

Pfizer | 09/06/2026 | By News Bureau

Pfizer's Berobenatide Shows Strong Phase 2b Results with Monthly Dosing

Pfizer’s GLP-1 receptor agonist berobenatide demonstrated robust efficacy and favorable tolerability in a Phase 2b trial, supporting once-monthly dosing.

Pfizer | 08/06/2026 | By News Bureau

Pfizer's BRAFTOVI Nearly Doubles Progression-Free Survival in Metastatic Colorectal Cancer

Pfizer reported phase 3 BREAKWATER trial results showing that the BRAFTOVI regimen nearly doubled median Progression-Free Survival (PFS) in patients with metastatic colorectal cancer, reducing the risk of disease progression or death by 56 percent and the risk of death by 44 percent compared with standard chemotherapy in BRAF V600E-mutant disease.

Pfizer | 01/06/2026 | By News Bureau |  104